Frontier Capital Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Frontier Capital Management’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,056,607	Closed	-$40M	–	351
2018 Q1	$40M	Buy	2,056,607 +592,359	+40%	+$11.6M	0.29%	137
2017 Q4	$24.4M	Sell	1,464,248 -156,300	-10%	-$2.86M	0.18%	177
2017 Q3	$32.9M	Buy	1,620,548 +34,720	+2%	+$664K	0.24%	153
2017 Q2	$25.5M	Buy	1,585,828 +478,168	+43%	+$7.06M	0.19%	164
2017 Q1	$14M	Buy	+1,107,660	New	+$13.4M	0.1%	219

Frontier Capital Management's IPXL Position: Q2 2018 in Review

Frontier Capital Management sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 2,056,607 shares — an estimated $40M sold.

Frontier Capital Management first reported a position in IPXL in Q1 2017 and held it in 5 quarters. The position peaked at $40M in Q1 2018. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.

Frontier Capital Management reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
Frontier Capital Management sold 2,056,607 Impax Laboratories, Inc. shares in Q2 2018, an estimated $40M.
Frontier Capital Management first reported a position in Impax Laboratories, Inc. in Q1 2017 and held it in 5 quarters.
Frontier Capital Management's Impax Laboratories, Inc. position peaked at $40M in Q1 2018.
1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.

Based on Frontier Capital Management's 13F filing for Q2 2018, filed 3 Aug 2018.